# Peptide-specific Vaccination in HLA-A*02 Positive Patients With Biochemical Recurrence After Radical Prostatectomy

> **NCT02452307** · PHASE1,PHASE2 · UNKNOWN · sponsor: **University Hospital Tuebingen** · enrollment: 36 (actual)

## Conditions studied

- Recurrent Prostate Cancer

## Interventions

- **BIOLOGICAL:** Peptide vaccine
- **DRUG:** Montanide ISA-51
- **DRUG:** Granulocyte macrophage colony stimulating factor (GM-CSF)
- **DRUG:** Imiquimod
- **DRUG:** mRNA
- **DRUG:** Protamin
- **PROCEDURE:** local hyperthermia

## Key facts

- **NCT ID:** NCT02452307
- **Lead sponsor:** University Hospital Tuebingen
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2004-04
- **Primary completion:** 2017-10
- **Final completion:** 2017-10
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2017-08-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02452307

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02452307, "Peptide-specific Vaccination in HLA-A*02 Positive Patients With Biochemical Recurrence After Radical Prostatectomy". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02452307. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*